On Thursday and Friday this week, FDA convenes its highly anticipated public hearing on innovative routes to nonprescription drug status. "The Tan Sheet's" March 19 issue continues to delve into the mechanics behind this "new paradigm" and the challenges ahead.
This week we also check in with Prestige Brands' efforts to resist Genomma Lab's unsolicited takeover bid and GlaxoSmithKline's latest OTC divestments, which did not include weight-loss drug alli.
Additionally, we've got stories on state anti-meth laws, nutritional marketing to the millennial generation, and Teva Pharmaceutical Industries' legal argument for Plan B One-Step OTC market exclusivity.
For much more, and "The Tan Sheet's" full March 19 table of contents, click here.
"The Tan Sheet" is your source for the most comprehensive and in-depth coverage of the OTC drug and nutritional industries. Start your free trial subscription here -- no credit card required.
Your company or organization may already provide access to "The Tan Sheet." To find out if you should have access, email custcare@elsevier.com.
Also, follow "The Tan Sheet" on Twitter and Facebook.
--Dan Schiff (d.schiff@elsevier.com)
